CHMP recommends approval of Ablynx’s Cablivi to treat aTTP

This article was originally published here

Sanofi said that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its subsidiary Ablynx’s Cablivi (caplacizumab) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply